Dr. Randy Sweis on Impact of Atezolizumab Approval in Bladder Cancer

Video

Randy Sweis, MD, clinical instructor, University of Chicago Medical Center, discusses how the recent approval of atezolizumab will change the treatment paradigm for bladder cancer.

The approval will dramatically change bladder cancer treatment, says Sweis. For patients that have had no response or a recurrence to chemotherapy, there was previously very few options that were effective and had minimal toxicities. Now oncologists can offer these patients atezolizumab, he says.

The approval will also change clinical trials. Many patients coming to trials will now have already received immunotherapies. Phase I trials are planned for patients that have had recurrences while on a PD-1 agent. These trials are typically investigating immunotherapy combinations, says Sweis.

Related Videos
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute